JPWO2022068809A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022068809A5 JPWO2022068809A5 JP2023519496A JP2023519496A JPWO2022068809A5 JP WO2022068809 A5 JPWO2022068809 A5 JP WO2022068809A5 JP 2023519496 A JP2023519496 A JP 2023519496A JP 2023519496 A JP2023519496 A JP 2023519496A JP WO2022068809 A5 JPWO2022068809 A5 JP WO2022068809A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 78
- 239000000427 antigen Substances 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- 239000012634 fragment Substances 0.000 claims 28
- 150000001413 amino acids Chemical class 0.000 claims 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 18
- 230000035772 mutation Effects 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 8
- 229940127121 immunoconjugate Drugs 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 229940126586 small molecule drug Drugs 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102000002029 Claudin Human genes 0.000 claims 1
- 108050009302 Claudin Proteins 0.000 claims 1
- 102220473219 Glycodelin_H52A_mutation Human genes 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011054187.5 | 2020-09-29 | ||
| CN202011054187 | 2020-09-29 | ||
| PCT/CN2021/121285 WO2022068809A1 (zh) | 2020-09-29 | 2021-09-28 | 抗cd3抗体以及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023543826A JP2023543826A (ja) | 2023-10-18 |
| JP2023543826A5 JP2023543826A5 (https=) | 2024-10-07 |
| JPWO2022068809A5 true JPWO2022068809A5 (https=) | 2024-10-07 |
Family
ID=80949658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519496A Pending JP2023543826A (ja) | 2020-09-29 | 2021-09-28 | 抗ｃｄ３抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230374132A1 (https=) |
| EP (1) | EP4223777A4 (https=) |
| JP (1) | JP2023543826A (https=) |
| KR (1) | KR20230079409A (https=) |
| CN (2) | CN121108344A (https=) |
| AU (1) | AU2021353368B2 (https=) |
| CA (1) | CA3196933A1 (https=) |
| TW (2) | TWI898054B (https=) |
| WO (1) | WO2022068809A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117897404A (zh) * | 2021-08-02 | 2024-04-16 | 信达生物制药(苏州)有限公司 | 抗CD79b×CD3双特异性抗体及其用途 |
| CN119604525A (zh) | 2022-07-22 | 2025-03-11 | 信达生物制药(苏州)有限公司 | 促进多特异性抗体的重链和轻链同源配对的突变体 |
| CN115792242A (zh) * | 2022-11-23 | 2023-03-14 | 苏州逻晟生物医药有限公司 | 一种测定抗cd70单克隆抗体直接激活cd70下游通路能力的方法 |
| WO2024251154A1 (zh) | 2023-06-06 | 2024-12-12 | 信达生物制药(苏州)有限公司 | 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途 |
| WO2025131077A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3多特异性抗体及用途 |
| WO2025247325A1 (en) * | 2024-05-30 | 2025-12-04 | Hanx Biopharmaceuticals, (Wuhan) Ltd. | Antibody-drug conjugates targeting trbv12 and uses thereof |
| WO2026006494A1 (en) * | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-cd3 antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU2004213053C1 (en) | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| CA2898100C (en) * | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| US11603405B2 (en) * | 2018-05-24 | 2023-03-14 | Janssen Biotech, Inc. | Anti-CD3 antibodies and uses thereof |
| CN111518214B (zh) * | 2019-02-03 | 2023-09-22 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的双特异性抗体及其制备方法和应用 |
| CA3118397A1 (en) * | 2018-11-01 | 2020-05-07 | Shandong Newtime Pharmaceutical Co., Ltd. | Bispecific antibody targeting cd3 and bcma, and uses thereof |
| CN110914296B (zh) * | 2019-02-22 | 2021-02-19 | 武汉友芝友生物制药有限公司 | 改造的Fc片段，包含其的抗体及其应用 |
| CN111662382A (zh) * | 2019-03-06 | 2020-09-15 | 瑞阳(苏州)生物科技有限公司 | 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用 |
| KR20220071263A (ko) * | 2019-09-30 | 2022-05-31 | 하버 바이오메드 (쑤저우) 컴퍼니 리미티드 | Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도 |
| US20250074996A1 (en) * | 2021-02-19 | 2025-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF |
-
2021
- 2021-09-28 KR KR1020237014541A patent/KR20230079409A/ko active Pending
- 2021-09-28 CA CA3196933A patent/CA3196933A1/en active Pending
- 2021-09-28 AU AU2021353368A patent/AU2021353368B2/en active Active
- 2021-09-28 CN CN202511420584.2A patent/CN121108344A/zh active Pending
- 2021-09-28 JP JP2023519496A patent/JP2023543826A/ja active Pending
- 2021-09-28 TW TW110136040A patent/TWI898054B/zh active
- 2021-09-28 US US18/246,930 patent/US20230374132A1/en active Pending
- 2021-09-28 CN CN202180066476.3A patent/CN116261590B/zh active Active
- 2021-09-28 TW TW114131058A patent/TW202547880A/zh unknown
- 2021-09-28 EP EP21874469.6A patent/EP4223777A4/en active Pending
- 2021-09-28 WO PCT/CN2021/121285 patent/WO2022068809A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220340673A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2020522280A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JPWO2022175255A5 (https=) | ||
| CA3236646A1 (en) | Novel anti-l1cam antibody | |
| TW202434296A (zh) | 一種ｆａｐ／ｃｄ４０結合分子的醫藥組成物及其醫藥用途 | |
| KR20200132996A (ko) | 세포 연계 결합 분자 | |
| CA3255552A1 (en) | TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY | |
| JPWO2022068809A5 (https=) | ||
| EP4025612B1 (en) | Anti-fucosyl-gm1 antibodies | |
| JPWO2019228514A5 (https=) | ||
| JPWO2023078382A5 (https=) | ||
| JPWO2023061505A5 (https=) | ||
| JPWO2020218951A5 (https=) | ||
| EP4428158A1 (en) | Lung cancer targeting human antibodies and therapeutic uses thereof | |
| JPWO2022135467A5 (https=) | ||
| JPWO2022068810A5 (https=) | ||
| WO2024131846A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| JPWO2021069670A5 (https=) | ||
| WO2024131835A1 (en) | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof | |
| JPWO2023011338A5 (https=) | ||
| RU2025134255A (ru) | Конъюгат антитела к рецептору эпидермального фактора роста (egfr) и лекарственного средства и его применение |